VIRTUAL SESSIONS ARE NOT LIVE STREAMED. THEY WILL BE RECORDED AND PUBLISHED LATER FOR VIEWING.
Sunday, October 13th
8:30am - 11:00am
Registration Open
9:30am - 10:30am
Plenary Session 9
Basic Science Plenary Session
Chair: Richard White
9:30am - 10:30am
A journey through the wilderness – cancer heterogeneity as challenge and opportunity
Andy Futreal
10:30am - 10:45am
Break
10:45am - 12:15pm
Plenary Session 10
Late Breaking Clinical Abstracts
Chair: Georgina Long
10:45am - 11:00am
Prospective multicenter evaluation (MERLIN_001 trial) of a clinicopathologic and gene expression profile test to predict sentinel node status in T1-T3 cN0 melanoma
Vernon Sondak
11:00am - 11:15am
A Phase 1 Clinical Trial Evaluating Exarafenib, a Selective Pan-RAF lnhibitor, as monotherapy and in combination with Binimetinib in NRAS-mutant (NRASMut) Melanoma (Mel)
Janice Mehnert
11:15am - 11:30am
A Phase II trial of Nivolumab (nivo) plus axitinib (axi) in patients (pts) with anti-PD1 refractory advanced melanoma (mel)
Yana Najjar
Neoadjuvant pembrolizumab plus lenvatinib (NeoIT-L) in resectable stage III melanoma patients (pts) (NeoPele): analysis of the tumor microenvironment (TME) and the peripheral immune profile correlated to pathological response.
11:30am - 11:45am
Ines Silva
11:45am - 12:00pm
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: Survival outcomes and the impact of the microbiome from the NeoACTIVATE trial
Matthew Block
12:00pm - 12:15pm
A post-hoc analysis of patients (pts) treated on Phase 3 PIVOTAL trial of neoadjuvant intralesional Daromun vs upfront surgery in stage 3, surgically resectable, advanced melanoma
Paolo Ascierto
12:15pm - 12:30pm
Closing Remarks